Brind.

Phase 3 Clinical Data on Investigational mRNA Therapy Presented at ESMO Congress

Steady: 1 in the last 7 days Updated thursday

The latest in this situation

  1. Eisai presented research at the European Society for Medical Oncology (ESMO) Congress.
  2. Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.

How it started

1 report, 1 independent, last reported Sep 21. The briefing below covers this first event.

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Researchers presented Phase 3 clinical data at the European Society for Medical Oncology Congress on September 21, 2026. The presentations included a Presidential Symposium led by Georgina V. Long regarding the Phase 3 study of intismeran autogene combined with pembrolizumab for adjuvant treatment of resected stage IIB-IV melanoma. Additionally, David J. Pinato presented findings from a Phase I study on adjuvant intismeran autogene combined with FOLFIRINOX for pancreatic ductal adenocarcinoma.

From pr-inside.com

Why it matters

Some supportBrind's analysis of the reports

The presentations concern intismeran autogene, an investigational mRNA-based individualized neoantigen therapy. The findings are relevant to the ongoing development pipeline of Moderna, which is involved in the research. The data could influence future regulatory pathways for advanced cancer treatments.

From pr-inside.com

Who's involved

  • European Society for Medical OncologyProfessional organization hosting the presentations
  • ModernaCompany presenting research findings at the congress
  • Georgina V. LongResearcher leading the Presidential Symposium on Phase 3 data
  • David J. PinatoMedical oncologist presenting on adjuvant cancer treatment
  • Charu AggarwalPulmonary oncologist whose data was presented at the congress

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

How it developed

Newest first. Tap a step to see who reported it.
  1. Eisai presented research at the European Society for Medical Oncology (ESMO) Congress.Sub-event
  2. Phase 3 clinical data was presented by researchers at the ESMO Congress.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped